Growth factors during HCV therapy may be "cost-effective", but are they "effective"?

Hepatology. 2006 Dec;44(6):1400-3. doi: 10.1002/hep.21426.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Algorithms
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use
  • Cost-Benefit Analysis
  • Erythropoietin / therapeutic use
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / economics
  • Humans
  • Intercellular Signaling Peptides and Proteins / economics
  • Intercellular Signaling Peptides and Proteins / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Ribavirin / adverse effects
  • Ribavirin / therapeutic use
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Intercellular Signaling Peptides and Proteins
  • Erythropoietin
  • Ribavirin